ClinicalTrials.gg
CompletedNCT00254293Updated Apr 8, 2014Results posted

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

A Phase 1/2 interventional study of Abatacept or Placebo (both as IV & SC Solution) and Abatacept or Placebo (both as IV & SC Solution) in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-08.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
38th of 63
87 · median 119
Started
2006
with 2 others
Phase 1/2
2 of 63
none open now
Registered
11th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 38th largest by enrollment, is one of 3 that started in 2006, is one of 2 in phase 1/2, and was the 11th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet ARA criteria for diagnosis of RA with active disease.
  • RA diagnosis for at least 1 year.
  • > = 6 swollen joints.
  • > = 8 tender joints.
  • Taking methotrexate (MTX) or MTX plus not more than 1 added oral DMARD for > = 3 months and stable for 28 days prior to dosing.

Exclusion criteria

Exclusion Criteria:

  • Serious acute or bacterial infection in last 3 months.
  • Chronic or recurrent bacterial infections.
  • History of TB within previous 3 years or old TB not adequately treated.
  • Specific lab test abnormalities
  • History of cancer within 5 years.
  • Exposure to CTLA4Ig (Cytotoxic T-lymphocyte (T-cell)-associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other drug or biologic.
  • Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, D-Penicillamine or calcineurin inhibitors.
  • Exposure to .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Placebo comparator
    Group 1 (weight < 60 kg)

    Drug: Abatacept or Placebo (both as IV & SC Solution)

  • Placebo comparator
    Group 2 (weight < 60 kg)

    Drug: Abatacept or Placebo (both as IV & SC Solution)

  • Placebo comparator
    Group 3 (weight 60-100 kg)

    Drug: Abatacept or Placebo (both as IV & SC solution)

  • Placebo comparator
    Group 4 (weight > 100 kg)

    Drug: Abatacept or Placebo (both as IV & SC solution)

  • Placebo comparator
    Group 5 (weight > 100 kg)

    Drug: Abatacept or Placebo (both as IV & SC solution)

  • Experimental
    Abatacept

    Long Term

    Drug: Abatacept

Interventions

  • DrugAbatacept or Placebo (both as IV & SC Solution)

    Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

    Also known as: Orencia

  • DrugAbatacept or Placebo (both as IV & SC Solution)

    Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

    Also known as: Orencia

  • DrugAbatacept or Placebo (both as IV & SC solution)

    Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

    Also known as: Orencia

  • DrugAbatacept or Placebo (both as IV & SC solution)

    Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

    Also known as: Orencia

  • DrugAbatacept or Placebo (both as IV & SC solution)

    Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).

    Also known as: Orencia

  • Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly

06

What researchers measure

Primary outcomes

  1. Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS)

    Participants received abatacept while also receiving DMARDS over a short term (ST) 12 Week period. To eliminate contribution from the IV loading dose of abatacept during the short term study period, Cmin values were selected from Days 71 to 85, when contribution from IV was negligible. Minimum trough serum concentration of abatacept (Cmin) was measured in micrograms/milliliter (µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Days 71 to 85

  2. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Reported During the Variable Dosing Phase of the Long Term Period (LTE)

    AEs during variable dose phase of LTE + 56 days post last dose in the variable dose phase or start of the fixed dose phase, which ever came first; includes deaths reported during the variable dose phase including those that occurred greater than 56 days after last dose. Medical Dictionary for Regulatory Activities (MedDRA) version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug. Data presented by treatment the participant was randomized to and not what they actually received.

    Time frame: Day 85 to 56 days post last dose

  3. Number of Participants With Pre-specified AEs of Special Interest in the Variable Dosing Phase of Long Term Extension (LTE)

    LTE period with variable abatacept dosing starting on Day 85 and continuing until Day 533 when LTE fixed dosing started. AEs of special interest: infection and/or infestation; neoplasms (malignant); pre-specified autoimmune disorder; infusional AEs (peri-infusional: pre-specified AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: pre-specified AEs occurring during the first hour after the start of the IV loading dose; systemic injection site reactions (SIR): pre-specified AEs for SIR; local injection site reaction: pre-specified AEs for local site reaction. Data are presented by treatment the participant was randomized to and not what they actually received.

    Time frame: Day 85 to Day 533

  4. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Summarized Over the Entire Long Term Extension (LTE) Period (Both Variable and Fixed Dosing)

    On Day 85 participants rolled over into the LTE with variable dose phase first and at Day 533, a fixed dose phase of 125 mg abatacept SC weekly, irrespective of body weight. This summary includes AEs reported during entire LTE treatment plus 56 days post last dose; includes all deaths reported during the LTE including those that occurred greater than 56 days after last dose. MedDRA version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Day 533 to 56 Days Post last dose

Secondary outcomes

  1. Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS

    Peak serum concentration (Cmax) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78. Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001, Upper limit of quantification (ULOQ) was 0.030. Cmax measured in micrograms per milliliter(µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 71 to Day 78

  2. Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS

    The steady-state pharmacokinetic parameter AUC(TAU) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78 (TAU=7 days). Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001; Upper limit of quantification (ULOQ) was 0.030. AUC(TAU) measured in in micrograms\*hours per milliliter (µg\*h/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 71 to Day 78

  3. Short Term Period: Summary of Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs During 12 Weeks of Treatment With Either Abatacept or Placebo

    Number of Participants with Adverse events (AEs), Serious AEs, discontinuations due to AEs, or Deaths occurring while participant was on treatment from Day 1 (treatment) to Day 85 or early termination from the study. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  4. Short Term Period: Number of Participants With Pre-specified Adverse Events (AEs) of Special Interest After Administration of Abatacept or Placebo Over 12 Weeks

    AEs of special interest: infection and/or infestation; neoplasms (benign, malignant, unspecified; autoimmune disorder; infusional AEs (peri-infusional: AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: AEs occurring during the first hour after the start of the IV loading dose; injection site AEs: AEs occurring at the site of the SC injection. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  5. Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration

    Serum samples were obtained on Days 1, 8, 15, 29, 57 and day of discharge (Day 85 or earlier) for determination of presence of rheumatoid factor (RF). Baseline was defined as Day 1 to calculate percent change. Lower limit of quantitation (LLQ) was 5 Units/milliliter (U/mL). Values below LLQ were set to 2.5 U/mL. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  6. Short Term Period: Number of Participants With Laboratory Abnormalities in Hematology at Baseline (Day 1) to End of Period (Day 85)

    Blood samples were obtained: At screening, within 24 hours prior to study drug administration on Day 1, on Days 15, 29, 57 and at study discharge. Baseline (BL) defined as Day 1 prior to treatment. Common toxicity criteria (CTC), Version 3 used to assess parameters. lower limit of normal (LLN). ANC=absolute neutrophil count. White blood cells Grade (Gr) 1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L. ANC Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L. Lymphocytes Gr 1: \<LLN to 3.0, Gr 2: 2.0 \< 3.0, Gr 3: 1.0 to \< 2.0, Gr 4; \< 1.0. Platelet count Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0 to 10\^9/L. Hemoglobin Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL. Hematocrit (%): \<0.75\*pre-treatment. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  7. Short Term Period: Number of Participants With Laboratory Abnormalities in Serum Chemistry at Baseline and on Treatment up to Day 85

    Screening, BL, Days 15, 29, 57, 85 or discharge. Upper limit of normal (ULN). CTC grade (Gr): Alanine transaminase Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Aspartate aminotransferase Gr 1: \>ULN to 2.5\*ULN; Gr 2:\>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. G-Glutamyl Transferase (U/L) Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Alkaline phosphatase (U/L) Gr 1:\>ULN to 2.5\*ULN, Gr2:\>2.5 to 5.0\*ULN, Gr3:\>5.0 to 20.0\*ULN, Gr4: \>20.0\*ULN; creatinine (mg/dL) Gr 1: \>ULN to 1.5\*ULN; Gr 2: \>1.5 to 3.0\*ULN; Gr 3: \>3.0 to 6.0\*ULN; Gr 4: \>10.0\*ULN. Albumin (g/dL) Gr 1:\<LLN to 3.0; Gr 2:\<3.0 to 2.0; Gr 3: \<2.0. Uric Acid (mg/dL)Gr 1: \>1.0 x ULN to 10.0; Gr 4: \>10.0. Sodium (mEq/L) Gr 1: \>ULN to 150; Gr 2: \>150 to 155; Gr 3: \>155 to 160; Gr 4: \> 160. Potassium (mEq/L) Gr 1: \>ULN to 5.5; Gr 2: \>5.5 to 6.0; Gr 3: \>6.0 to 7.0; Gr 4: \>7.0. Data presented by treatment participant actually received.

    Time frame: Day 1 to Day 85 (or early termination)

  8. Short Term Period: Mean Change From Baseline at Day 85 in Blood Pressure After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

    Blood pressure (systolic and diastolic) was recorded while the participant was seated during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, blood pressure was recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Blood pressure was measured in millimeters of mercury (mm Hg). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  9. Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

    Pulse rate was taken while participant was seated. Pulse rate was recorded during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, vital signs were recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Pulse rate measured in beats/min (bpm). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Day 1 to Day 85 (or early termination)

  10. Short Term Period: Mean Change From Screening to Day 85 in Electrocardiogram (QT, PR Intervals, QRS Width) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

    A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. QT interval, PR interval and QRW Width were reported in milliseconds (msec). If no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Screening to Day 85 (or early termination)

  11. Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

    A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. Heart Rate was reported in beats per minute (bpm). In no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

    Time frame: Screening to Day 85 (or early termination)

  12. Overall Study ST and LTE Periods: Number of Participants With Anti-abatacept Antibodies and/or Anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibodies

    Assessment of positive antibody response based upon analysis using a validated enzyme-linked immunosorbent assay (ELISA) with a cut-off value. CTLA4 is a protein receptor that downregulates the immune system. Short Term (ST) period was initial 12 Weeks of the study. Overall LTE includes both the variable and fixed abatacept dosing periods and was from the end of the ST period (Day 85) up to 168 days post last dose (treatment in LTE ranged from 4.4 to 74.2 months. Data in the ST period are summarized by the treatment the participants actually received, while the LT period data are summarized by treatment the participant was randomized to receive.

    Time frame: ST: Day 1 to Day 85; LTE: Day 85 to 168 days post last dose

07

Results

Posted Apr 8, 2014
Limitations and caveats
Error resulted in 4 participants being treated with study drug they were not randomized to receive. ST data were summarized by study drug participants actually received while LT data were summarized by what participants were randomized to receive.

Participant flow

Short term (12 week) randomized Period: started January 2006/completed May 2007. Long term extension (LTE): started April 2006/completed July 2012. During LTE: variable dose period and fixed dose period. Patients with active Rheumatoid Arthritis (RA) and receiving disease modifying anti-rheumatic drugs (DMARDS) were eligible to participate.

Short Term (12 Week) Randomized Dosing
Participant flow — Short Term (12 Week) Randomized Dosing
MilestoneGroup 1: 500 mg IV/75 mg SCGroup 2: 500 mg IV/125 mg SCGroup 3 : 750 mg IV/125 mg SCGroup 4: 1000mg IV/125 mg SCGroup 5: 1000 mg IV/200 mg SCPlaceboFixed Dose 125 mg Abatacept
Started742965170
Completed732655170
Not completed0131000
Withdrew: Adverse event0101000
Withdrew: Lost to follow-up0010000
Withdrew: Poor/non-compliance by participant0020000
LTE Open Label Variable SC Dosing
Participant flow — LTE Open Label Variable SC Dosing
MilestoneGroup 1: 500 mg IV/75 mg SCGroup 2: 500 mg IV/125 mg SCGroup 3 : 750 mg IV/125 mg SCGroup 4: 1000mg IV/125 mg SCGroup 5: 1000 mg IV/200 mg SCPlaceboFixed Dose 125 mg Abatacept
Started1104201000
Completed80320800
Not completed30100200
Withdrew: Death0010000
Withdrew: Adverse event1020100
Withdrew: Lack of efficacy2020100
Withdrew: Lost to follow-up0010000
Withdrew: Withdrawal by subject0010000
Withdrew: Poor or non-compliance0010000
Withdrew: Other0020000
LTE Open Label Fixed Dosing
Participant flow — LTE Open Label Fixed Dosing
MilestoneGroup 1: 500 mg IV/75 mg SCGroup 2: 500 mg IV/125 mg SCGroup 3 : 750 mg IV/125 mg SCGroup 4: 1000mg IV/125 mg SCGroup 5: 1000 mg IV/200 mg SCPlaceboFixed Dose 125 mg Abatacept
Started00000048
Completed00000035
Not completed00000013
Withdrew: Death0000003
Withdrew: Adverse event0000001
Withdrew: Lack of efficacy0000003
Withdrew: Lost to follow-up0000001
Withdrew: Withdrawal by subject0000003
Withdrew: Poor or non-compliance0000001
Withdrew: Other0000001

Outcome measures

PrimaryShort Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS)

Participants received abatacept while also receiving DMARDS over a short term (ST) 12 Week period. To eliminate contribution from the IV loading dose of abatacept during the short term study period, Cmin values were selected from Days 71 to 85, when contribution from IV was negligible. Minimum trough serum concentration of abatacept (Cmin) was measured in micrograms/milliliter (µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Days 71 to 85
Reported as:
Geometric mean · µg/mL
Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS)
µg/mLGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)
Day 7122.64 ± 20.1328.03 ± 42.1324.05 ± 40.6516.22 ± 24.3926.52 ± 56.53
Day 7821.66 ± 19.9934.17 ± 29.4924.41 ± 52.3511.57 ± 32.2529.21 ± 52.96
Day 8523.62 ± 31.6336.73 ± 31.6424.93 ± 38.4213.01 ± 41.3527.53 ± 58.87
SecondaryShort Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS

Peak serum concentration (Cmax) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78. Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001, Upper limit of quantification (ULOQ) was 0.030. Cmax measured in micrograms per milliliter(µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 71 to Day 78
Reported as:
Geometric mean · µg/mL
Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS
µg/mLGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)
Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS26.3 ± 29.534.9 ± 46.631.9 ± 42.814.7 ± 44.341.7 ± 41.2
SecondaryShort Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS

The steady-state pharmacokinetic parameter AUC(TAU) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78 (TAU=7 days). Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001; Upper limit of quantification (ULOQ) was 0.030. AUC(TAU) measured in in micrograms\*hours per milliliter (µg\*h/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 71 to Day 78
Reported as:
Geometric mean · µg*h/mL
Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS
µg*h/mLGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)
Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS4066 ± 22.26699 ± 20.74607 ± 38.62555 ± 30.15849 ± 40.5
PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Reported During the Variable Dosing Phase of the Long Term Period (LTE)

AEs during variable dose phase of LTE + 56 days post last dose in the variable dose phase or start of the fixed dose phase, which ever came first; includes deaths reported during the variable dose phase including those that occurred greater than 56 days after last dose. Medical Dictionary for Regulatory Activities (MedDRA) version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug. Data presented by treatment the participant was randomized to and not what they actually received.

Time frame:
Day 85 to 56 days post last dose
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Reported During the Variable Dosing Phase of the Long Term Period (LTE)
participants75 mg SC Abatacept (Body Weight < 60 kg)125 mg SC Abatacept (Body Weight <60 to >100 kg)200 mg SC Abatacept (Body Weight > 100 kg)
Deaths010
Participants with SAEs2134
Participants with drug related SAEs121
Participants discontinued due to SAEs011
Participants with AEs9389
Participants with drug related AEs2203
Participants discontinued due to AEs121
SecondaryShort Term Period: Summary of Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs During 12 Weeks of Treatment With Either Abatacept or Placebo

Number of Participants with Adverse events (AEs), Serious AEs, discontinuations due to AEs, or Deaths occurring while participant was on treatment from Day 1 (treatment) to Day 85 or early termination from the study. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Number · participants
Short Term Period: Summary of Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs During 12 Weeks of Treatment With Either Abatacept or Placebo
participantsGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Deaths000000
Participants with SAEs011010
Participants with AEs53216511
Discontinued due to AEs010100
SecondaryShort Term Period: Number of Participants With Pre-specified Adverse Events (AEs) of Special Interest After Administration of Abatacept or Placebo Over 12 Weeks

AEs of special interest: infection and/or infestation; neoplasms (benign, malignant, unspecified; autoimmune disorder; infusional AEs (peri-infusional: AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: AEs occurring during the first hour after the start of the IV loading dose; injection site AEs: AEs occurring at the site of the SC injection. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Number · participants
Short Term Period: Number of Participants With Pre-specified Adverse Events (AEs) of Special Interest After Administration of Abatacept or Placebo Over 12 Weeks
participantsGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Number with Infection/Infestation events319314
Number with malignant neoplasm events000000
Number with autoimmune disorder events000000
Number with acute infusional events002100
Number with peri-infusional events004300
General disorders and injection site events0111321
SecondaryShort Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration

Serum samples were obtained on Days 1, 8, 15, 29, 57 and day of discharge (Day 85 or earlier) for determination of presence of rheumatoid factor (RF). Baseline was defined as Day 1 to calculate percent change. Lower limit of quantitation (LLQ) was 5 Units/milliliter (U/mL). Values below LLQ were set to 2.5 U/mL. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Mean · percentage of change from baseline
Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration
percentage of change from baselineGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration-1.50 ± 43.50-8.89 ± 3.14-17.69 ± 26.61-16.29 ± 16.24-19.32 ± 15.2143.72 ± 154.47
SecondaryShort Term Period: Number of Participants With Laboratory Abnormalities in Hematology at Baseline (Day 1) to End of Period (Day 85)

Blood samples were obtained: At screening, within 24 hours prior to study drug administration on Day 1, on Days 15, 29, 57 and at study discharge. Baseline (BL) defined as Day 1 prior to treatment. Common toxicity criteria (CTC), Version 3 used to assess parameters. lower limit of normal (LLN). ANC=absolute neutrophil count. White blood cells Grade (Gr) 1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L. ANC Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L. Lymphocytes Gr 1: \<LLN to 3.0, Gr 2: 2.0 \< 3.0, Gr 3: 1.0 to \< 2.0, Gr 4; \< 1.0. Platelet count Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0 to 10\^9/L. Hemoglobin Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL. Hematocrit (%): \<0.75\*pre-treatment. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Number · participants
Short Term Period: Number of Participants With Laboratory Abnormalities in Hematology at Baseline (Day 1) to End of Period (Day 85)
participantsGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Baseline (Day 1 prior to treatment) Total4315129
Grade 1 baseline4313128
Grade 2 baseline012003
Grade 3 baseline001000
Grade 4 baseline000000
Day 1 after treatment to Day 85 Total44201413
Grade 1 on treatment44171311
Grade 2 on treatment016013
Grade 3 on treatment000001
Grade 4 on treatment000000
SecondaryShort Term Period: Number of Participants With Laboratory Abnormalities in Serum Chemistry at Baseline and on Treatment up to Day 85

Screening, BL, Days 15, 29, 57, 85 or discharge. Upper limit of normal (ULN). CTC grade (Gr): Alanine transaminase Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Aspartate aminotransferase Gr 1: \>ULN to 2.5\*ULN; Gr 2:\>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. G-Glutamyl Transferase (U/L) Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Alkaline phosphatase (U/L) Gr 1:\>ULN to 2.5\*ULN, Gr2:\>2.5 to 5.0\*ULN, Gr3:\>5.0 to 20.0\*ULN, Gr4: \>20.0\*ULN; creatinine (mg/dL) Gr 1: \>ULN to 1.5\*ULN; Gr 2: \>1.5 to 3.0\*ULN; Gr 3: \>3.0 to 6.0\*ULN; Gr 4: \>10.0\*ULN. Albumin (g/dL) Gr 1:\<LLN to 3.0; Gr 2:\<3.0 to 2.0; Gr 3: \<2.0. Uric Acid (mg/dL)Gr 1: \>1.0 x ULN to 10.0; Gr 4: \>10.0. Sodium (mEq/L) Gr 1: \>ULN to 150; Gr 2: \>150 to 155; Gr 3: \>155 to 160; Gr 4: \> 160. Potassium (mEq/L) Gr 1: \>ULN to 5.5; Gr 2: \>5.5 to 6.0; Gr 3: \>6.0 to 7.0; Gr 4: \>7.0. Data presented by treatment participant actually received.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Number · participants
Short Term Period: Number of Participants With Laboratory Abnormalities in Serum Chemistry at Baseline and on Treatment up to Day 85
participantsGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Baseline (Day 1 prior to treatment) Total226147
Grade 1 baseline225147
Grade 2 baseline001002
Grade 3 baseline000000
Grade 4 baseline000000
Day 1 (after treatment) to Day 85 Total54183415
Grade 1 on treatment50183315
Grade 2 on treatment104004
Grade 3 on treatment000011
Grade 4 on treatment000010
SecondaryShort Term Period: Mean Change From Baseline at Day 85 in Blood Pressure After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

Blood pressure (systolic and diastolic) was recorded while the participant was seated during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, blood pressure was recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Blood pressure was measured in millimeters of mercury (mm Hg). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Mean · mm Hg
Short Term Period: Mean Change From Baseline at Day 85 in Blood Pressure After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
mm HgGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Change from baseline in Diastolic blood pressure-5.2 ± 10.00.0 ± 13.10.7 ± 7.53.5 ± 11.2-5.4 ± 9.61.8 ± 8.3
Change from baseline in Systolic blood pressure-4.0 ± 12.1-6.3 ± 6.80.3 ± 17.8-0.8 ± 8.2-4.2 ± 10.50.2 ± 12.1
SecondaryShort Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

Pulse rate was taken while participant was seated. Pulse rate was recorded during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, vital signs were recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Pulse rate measured in beats/min (bpm). Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Day 1 to Day 85 (or early termination)
Reported as:
Mean · bpm
Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
bpmGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)Placebo (by Body Weight Category)
Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS-2.9 ± 10.00.3 ± 11.1-0.6 ± 9.53.5 ± 10.5-11.4 ± 9.0-1.0 ± 7.1
SecondaryShort Term Period: Mean Change From Screening to Day 85 in Electrocardiogram (QT, PR Intervals, QRS Width) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. QT interval, PR interval and QRW Width were reported in milliseconds (msec). If no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Screening to Day 85 (or early termination)
Reported as:
Mean · msec
Short Term Period: Mean Change From Screening to Day 85 in Electrocardiogram (QT, PR Intervals, QRS Width) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
msecAll Treated Participants
Change from Screening in QT interval (N=52)-1.47 ± 24.72
Change from Screening in PR interval (N=51)5.28 ± 21.10
Change from Screening in QRS Width (N=52)0.22 ± 11.03
PrimaryNumber of Participants With Pre-specified AEs of Special Interest in the Variable Dosing Phase of Long Term Extension (LTE)

LTE period with variable abatacept dosing starting on Day 85 and continuing until Day 533 when LTE fixed dosing started. AEs of special interest: infection and/or infestation; neoplasms (malignant); pre-specified autoimmune disorder; infusional AEs (peri-infusional: pre-specified AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: pre-specified AEs occurring during the first hour after the start of the IV loading dose; systemic injection site reactions (SIR): pre-specified AEs for SIR; local injection site reaction: pre-specified AEs for local site reaction. Data are presented by treatment the participant was randomized to and not what they actually received.

Time frame:
Day 85 to Day 533
Reported as:
Number · participants
Number of Participants With Pre-specified AEs of Special Interest in the Variable Dosing Phase of Long Term Extension (LTE)
participants75 mg SC Abatacept125 mg SC Abatacept200 mg SC Abatacept
Number with Serious Infection/Infestation112
Number with Malignant Neoplasms151
Number with Autoimmune Disorder010
Number with Acute Infusional Event000
Number with Serious Systemic injection Reaction000
Number with Local Injection Site Reaction040
SecondaryShort Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS

A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. Heart Rate was reported in beats per minute (bpm). In no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.

Time frame:
Screening to Day 85 (or early termination)
Reported as:
Mean · bpm
Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
bpmAll Treated Participants
Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS0.51 ± 8.43
PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Summarized Over the Entire Long Term Extension (LTE) Period (Both Variable and Fixed Dosing)

On Day 85 participants rolled over into the LTE with variable dose phase first and at Day 533, a fixed dose phase of 125 mg abatacept SC weekly, irrespective of body weight. This summary includes AEs reported during entire LTE treatment plus 56 days post last dose; includes all deaths reported during the LTE including those that occurred greater than 56 days after last dose. MedDRA version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Day 533 to 56 Days Post last dose
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Summarized Over the Entire Long Term Extension (LTE) Period (Both Variable and Fixed Dosing)
participantsSC Abatacept
Deaths6
Participants with SAEs35
Participants with Drug Related SAEs7
Participants Discontinued due to SAEs3
Participants with AEs61
Participants with Drug Related AEs34
Participants Discontinued due to AEs5
SecondaryOverall Study ST and LTE Periods: Number of Participants With Anti-abatacept Antibodies and/or Anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibodies

Assessment of positive antibody response based upon analysis using a validated enzyme-linked immunosorbent assay (ELISA) with a cut-off value. CTLA4 is a protein receptor that downregulates the immune system. Short Term (ST) period was initial 12 Weeks of the study. Overall LTE includes both the variable and fixed abatacept dosing periods and was from the end of the ST period (Day 85) up to 168 days post last dose (treatment in LTE ranged from 4.4 to 74.2 months. Data in the ST period are summarized by the treatment the participants actually received, while the LT period data are summarized by treatment the participant was randomized to receive.

Time frame:
ST: Day 1 to Day 85; LTE: Day 85 to 168 days post last dose
Reported as:
Number · participants
Overall Study ST and LTE Periods: Number of Participants With Anti-abatacept Antibodies and/or Anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibodies
participantsGroup 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)LTE (Variable and Fixed Dosing Abatacept)
Number with anti-abatacept antibodies0001011
Number with anti-CTLA4 antibodies000001

Adverse events

Collected over Day 1 of short term study up to 71 months in the long term study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept 1000mg IV/125mg SC—1/6 (16.7%)6/6 (100%)
Abatacept 1000mg IV/200mg SC—0/5 (0%)5/5 (100%)
Abatacept 500mg IV/125mg SC—1/5 (20%)2/5 (40%)
Abatacept 500mg IV/75mg SC—0/6 (0%)5/6 (83.3%)
Abatacept 750mg IV/125mg SC—1/28 (3.6%)18/28 (64.3%)
Abatacept (LT) 125 mg SC—35/63 (55.6%)58/63 (92.1%)
Placebo (ST)—0/18 (0%)12/18 (66.7%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventAbatacept 1000mg IV/125mg SCAbatacept 1000mg IV/200mg SCAbatacept 500mg IV/125mg SCAbatacept 500mg IV/75mg SCAbatacept 750mg IV/125mg SCAbatacept (LT) 125 mg SCPlacebo (ST)
Wound infectionInfections and infestations0/60/51/50/60/280/630/18
Chest discomfortGeneral disorders1/60/50/50/60/280/630/18
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/50/50/60/281/630/18
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders1/60/50/50/60/280/630/18
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/60/50/50/60/281/630/18
Diastolic dysfunctionCardiac disorders1/60/50/50/60/280/630/18
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/50/50/60/287/630/18
OsteoarthritisMusculoskeletal and connective tissue disorders0/60/50/50/60/285/630/18
PneumoniaInfections and infestations0/60/50/50/60/284/630/18
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/60/50/50/60/284/630/18
Most frequent other events
Showing 10 of 98
Most frequent other events
EventAbatacept 1000mg IV/125mg SCAbatacept 1000mg IV/200mg SCAbatacept 500mg IV/125mg SCAbatacept 500mg IV/75mg SCAbatacept 750mg IV/125mg SCAbatacept (LT) 125 mg SCPlacebo (ST)
HeadacheNervous system disorders3/62/50/50/61/288/633/18
Upper respiratory tract infectionInfections and infestations1/60/50/50/63/2822/632/18
FallInjury, poisoning and procedural complications0/60/50/52/60/287/630/18
Oedema peripheralGeneral disorders2/61/50/50/60/2812/630/18
SinusitisInfections and infestations1/60/50/50/60/2814/630/18
Back painMusculoskeletal and connective tissue disorders0/60/50/51/63/2814/633/18
BronchitisInfections and infestations0/60/50/51/60/2813/631/18
CoughRespiratory, thoracic and mediastinal disorders0/60/50/51/62/2813/630/18
Urinary tract infectionInfections and infestations0/60/50/51/64/2813/630/18
Intraocular pressure increasedInvestigations0/61/50/50/60/281/630/18

Baseline characteristics

Baseline includes all participants enrolled and treated. Baseline parameters are presented for each arm but the total value for baseline mean age and standard deviation (SD) includes all participants in LTE. Data are presented by treatment the participant actually received, not to what they were randomized to receive.

Age, Continuous
Age, Continuous(years)Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)PlaceboTotal
Mean72 ± 564 ± 1059 ± 1251 ± 955 ± 959 ± 1160 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)PlaceboTotal
Female7326541257
Male01311511
Region of Enrollment
Region of Enrollment(participants)Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg)Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg)Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg)Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg)Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg)PlaceboTotal
United States7429651768
08

Study locations

5 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32806, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • New Orleans Center For Clinical Research
    New Orleans, Louisiana 70119, United States
  • Davita Clinical Research
    Minneapolis, Minnesota 55404, United States
  • The Arthritis Clinic & Carolina Bone & Joint
    Charlotte, North Carolina 28210, United States
09

References and documents

Publications

  • Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, Aranda R, Becker JC, Qi K, Dougados M. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009 Apr;36(4):736-42. doi: 10.3899/jrheum.080813. Epub 2009 Feb 27. PubMed 19273451 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of May 2007 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 6 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2005
First posted
Nov 16, 2005
Start
Jan 2006
Primary completionActual
May 2007
CompletionActual
Jul 2012
Results first posted
Apr 8, 2014
Last update
Apr 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00254293
Responsible party
Sponsor
First posted
Nov 16, 2005
Start date
Jan 2006
Primary completion
May 2007
Completion
Jul 2012
Results posted
Apr 8, 2014
Last update
Apr 8, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion